5 Years of ME/CFS, Low Temp, and MCAS: A First 90 Days Decision Walkthrough

A Note on This Article

This is a scenario-based clinical decision walkthrough, not an individual patient case. It describes how the Scorch Protocol approaches a specific patient profile that is common enough in the chronic illness population to warrant focused walkthrough content. The decisions described reflect the protocol's standard approach to this profile. The framing is "if this is your situation, here is what the first 90 days look like." Individual variation is expected; the framework is consistent.

The Patient Profile

The walkthrough below applies to a patient with the following profile at protocol entry:

• ME/CFS diagnosis or de facto ME/CFS presentation
• Illness duration 5 years or longer
• Basal body temperature consistently below 96°F (averaging 95.0-95.8°F across multiple weeks of tracking)
• Active MCAS with documented reactivity to multiple foods, smells, and environmental triggers
• Currently on cromolyn sodium, antihistamines (H1 and often H2), often quercetin or DAO supplementation
• Significant post-exertional malaise (PEM): even minor activity produces 1-3 day crashes
• Functional capacity below 30% of pre-illness baseline
• Often on a restricted diet (low-histamine, low-FODMAP, sometimes carnivore) due to MCAS tolerance issues

If your situation matches this profile closely, the walkthrough below describes the protocol approach for your first 90 days. If you fit a different profile (more recent illness onset, higher baseline temperature, less MCAS involvement), the standard protocol entry described in the ME/CFS Recovery guide is the more appropriate starting point.

The Critical Difference for This Profile

The standard Scorch Protocol sequence for most chronic illness patients is: preparation → first dry fast → T3 therapy → refeeding plus hGH → rotation.

For the patient profile described above, this sequence is modified because the baseline temperature below 96°F and the severity of MCAS reactivity put the patient in the "lost-cause fasting" cohort where attempting an extended fast at the current baseline is more likely to produce symptoms than therapeutic benefit. The hyperosmotic stress of the fast on a metabolism this depleted is more than the system can productively respond to.

The modified sequence for this profile: extended preparation → T3 therapy first → tolerance-building with short fasts → first 5-day fast only after temperature has stabilized above 96°F → standard protocol from there.

The first 90 days for this patient are about establishing the metabolic foundation that makes extended fasting safe and productive, not about doing the fast itself.

Days 0-14: Baseline and Preparation

The first two weeks are entirely about establishing baseline and preparation, with no intervention beyond what the patient is already doing.

Daily basal body temperature tracking. Oral, before getting out of bed, for at least 14 days. The average over 14 days is the baseline that drives all subsequent decisions. If the average is below 96°F, the protocol modification applies.

Resting heart rate tracking. Morning, before getting out of bed. Establishes the cardiovascular baseline.

Symptom diary. Daily notes on energy level (1-10), brain fog level (1-10), MCAS reactivity (number of reactions, severity), PEM episodes (any activity that triggered a crash, severity, duration).

Baseline labs if accessible. TSH, free T4, free T3, reverse T3 (if available), morning cortisol, comprehensive metabolic panel, CBC. These are not required to begin the protocol (the protocol is designed for self-administration without lab access) but are useful when available.

Dietary baseline maintained. Whatever the patient is currently tolerating, continue. This is not the time to make dietary changes; the foundation has to be stable before changes are introduced.

Sleep hygiene. Optimized sleep is the foundation of everything that follows. Consistent bedtime, dark room, no screens for 2 hours pre-bed, temperature management. This is not optional; sleep is the single largest free recovery lever available.

End of week 2: baseline established. Decision point: does the temperature average confirm the low-temp protocol modification (below 96°F)? If yes, proceed to T3-first sequence. If no (temperature 96-97°F), discuss with prescriber whether standard or modified sequence is appropriate.

Days 14-30: T3 Therapy Initiation

For the sub-96°F patient profile, T3 begins before any extended fasting attempt. The reasoning: the cellular machinery is too suppressed to respond productively to the hyperosmotic stress of an extended fast at the current baseline. Restoring the cellular machinery first makes the fast both safer and more productive when it is eventually undertaken.

T3 prescription. Slow-release T3 (SR-T3) from a compounding pharmacy familiar with the protocol. The list of pharmacies page covers practical sourcing.

Starting dose: 12.5 mcg SR-T3 twice daily (morning and afternoon). Lower than the standard starting dose because severe MCAS patients are often more reactive to medication introduction.

MCAS management during T3 initiation. Continue all current MCAS medications. Some patients experience transient reactivity in the first week of T3 introduction; this typically resolves as the body adapts. If reactivity is severe or sustained, the T3 should be held for 3-5 days and restarted at a lower dose.

Tracking: continue daily basal body temperature and resting heart rate tracking. The T3 endpoint is gradual temperature rise.

End of week 4: T3 at 25-37.5 mcg/day, basal body temperature should be showing initial upward movement (0.2-0.5°F above baseline). If no movement, the dose climbs faster; if substantial movement, hold the current dose and observe.

Days 30-60: T3 Climb

The T3 climb continues through weeks 5-8. The pace is determined by temperature response:

• If temperature is climbing 0.1°F per week, the climb pace is appropriate
• If temperature is flat after 2 weeks at a given dose, increase by 12.5-25 mcg
• If temperature is climbing faster than 0.2°F per week, hold the dose and observe

By end of week 8, the typical patient in this profile is at 60-100 mcg SR-T3 daily and basal body temperature has climbed from sub-96°F baseline to 96.8-97.4°F average.

MCAS reactivity reduction. As cellular ATP supply restores, the regulatory mechanisms that hold MCAS in check come back online. Most patients in this profile begin reducing antihistamine and mast cell stabilizer doses during this window. The taper should be gradual (one medication at a time, half-dose reduction every 1-2 weeks).

Carbohydrate tolerance opening. The patient's restricted diet can begin expanding. Reintroduce one previously trigger food per week, with adequate gap to identify reactions. Carbohydrates specifically should be prioritized because they provide substrate for DIO2 conversion to endogenous T3 and signal abundance to the hypothalamus.

Energy improvement. Most patients in this profile experience first substantial energy improvement during weeks 5-8 of T3 therapy. This is the cellular ATP supply restoration translating into subjective energy.

PEM threshold widening. The activity level that triggers a PEM crash should be expanding. The patient should not push to test this; the widening will be observed as activities that previously crashed are no longer crashing.

End of week 8: T3 dose stable at temperature endpoint, basal body temperature averaging 97°F+, MCAS reactivity meaningfully reduced, dietary tolerance expanded, energy improved.

Days 60-90: First Short Fasts and Foundation Consolidation

With the metabolic foundation established by 8 weeks of T3 therapy, the first short fasts can be attempted.

Week 9: First 24-hour water fast. Tolerated as a tolerance test. The patient who could not have done this at baseline can now do it because the cellular machinery has been restored. Expected response: mild hunger, no significant MCAS flare, mild Herxheimer reaction possible in days 2-3 post-fast.

Week 10: 48-hour water fast. Same logic as above; tolerance is building.

Week 11: 72-hour water fast. This is the threshold beyond which the deeper therapeutic effects of fasting begin. Should produce noticeable post-fast improvement: clearer thinking for 1-2 weeks, energy improvement, MCAS reactivity reduction.

Week 12: 24-hour dry fast. First introduction to the dry fasting pathway. Brief enough to be tolerable, long enough to begin activating the hyperosmotic stress response. Pre-fast colon cleanse and liver flush completed in days prior.

End of week 13 (day 90): the patient is ready for the first 5-day dry fast. Basal body temperature averaging 97.5°F+ on T3, MCAS reactivity substantially reduced, dietary tolerance reasonable, PEM threshold significantly wider, multiple short fasts tolerated.

The first 5-day dry fast at this point will produce a substantively different result than it would have at protocol entry. The body has the metabolic capacity to respond productively to the hyperosmotic stress, the immune surge has somewhere to land, the cleanup window opens into a system that can use it.

What This 90-Day Window Buys

For this patient profile, the 90-day modification of the standard protocol order is what makes the protocol work at all. Attempting the standard sequence (dry fasting first, then T3) at a baseline temperature below 96°F is more likely to produce flares without therapeutic benefit than to produce sustainable recovery.

The 90-day window:

• Restores enough cellular ATP supply that the body can respond productively to extended fasting
• Reduces MCAS reactivity enough that the refeed window is not catastrophic
• Widens the PEM threshold enough that activity recovery during the fast and refeed does not crash the system
• Builds short-fast tolerance progressively rather than starting with an extended fast on a depleted base

Patients who attempt the standard sequence in this profile typically describe a pattern: the first extended fast produces brief improvement, then severe crash that takes months to recover from, often worse than the pre-protocol baseline. The 90-day preparation prevents this.

Continuing After Day 90

The protocol from day 90 onward follows the standard sequence:

• Days 90-100: First 5-day dry fast with proper preparation
• Days 100-130: Refeed and T3 cycle continuation
• Days 130-160: Second T3 cycle if needed, hGH discussion with prescriber
• Days 160-200: First hGH cycle begin (if T3 foundation stable)
• Days 200-365: Rebuild phase with continued T3 and hGH, biome rebuild, gradual return to pre-illness function

The total timeline for this patient profile is typically 12-18 months from protocol entry to substantial functional recovery, longer than the standard 9-12 month timeline because of the extended preparation window.

Decision Points to Watch

The walkthrough above describes the typical course. Several decision points commonly arise:

What if temperature does not rise on T3? If basal body temperature does not respond to gradually escalating SR-T3 doses up to 150 mcg by week 10, the issue is likely beyond Wilson's-style tissue thyroid resistance alone. Other mechanisms (severe metabolic collapse, untreated chronic infection, advanced HPT axis dysfunction) may be involved and warrant further medical evaluation.

What if MCAS reactivity does not reduce on T3? Some patients have MCAS driven primarily by other mechanisms (mast cell mutations, primary autoimmune drivers) that are not fully addressed by metabolic restoration alone. Continued MCAS management is appropriate in parallel; the protocol does not require MCAS resolution to proceed.

What if PEM gets worse during T3 initiation? This is uncommon but happens in a subset of patients. The first response is to slow the T3 climb; the second is to evaluate whether co-infection burden (Lyme, Babesia, etc.) is contributing.

What if energy improvement is dramatic and the patient overexerts? This is a real risk. Patients who feel substantially better on T3 often resume activities too quickly and trigger PEM crashes that set back the protocol. The protocol explicitly counsels against accelerated activity during weeks 4-8; the energy floor is rising but is not yet stable.

What if the first short fast triggers a severe MCAS flare? Drop back to shorter fast lengths and longer T3 stabilization before attempting again. The metabolic foundation may need more time before fasting is productive.

What This Walkthrough Is Not

This walkthrough is a clinical scenario decision tree. It is not:

• Individualized medical advice for any specific patient (every patient has variables this walkthrough cannot account for)
• A guaranteed outcome (response varies; the protocol is not a guaranteed cure)
• A substitute for working with prescribing physicians for T3, hGH, and MCAS medications
• A substitute for reading the full clinical context in the ME/CFS Recovery guide, the Long Covid Recovery guide, Long Covid and MCAS, and the relevant protocol pages

Where to Start

If the patient profile described matches your situation, the entry point is the same as the walkthrough begins: baseline tracking for 14 days, then discussion with a prescriber about T3 initiation, then the modified sequence described above. Read the ME/CFS Recovery guide for the full mechanism context, the T3 therapy complete guide for the T3-specific execution, and Long Covid and MCAS for the MCAS-specific implementation considerations.